Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert

Safety and efficacy of multiple cyclocoagulation of ciliary bodies by high-intensity focused ultrasound in patients with glaucoma

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Glaucoma

Session Date/Time: Sunday 11/09/2016 | 15:00-16:30

Paper Time: 16:20

Venue: Poster Village: Pod 3

First Author: : A.De Gregorio ITALY

Co Author(s): :    G. Stevan   S. Morselli           

Abstract Details


To describe outcomes of multiple high-intensity focused ultrasound (HIFU) treatments as therapy for uncontrolled glaucoma using a miniaturized delivery device (EyeOP1).


Ophthalmic Unit, San Bassiano Hospital, Bassano del Grappa, Italy


We performed a prospective non-comparative case series study in 24 eyes of 24 patients with uncontrolled primary and secondary glaucoma. A complete ophthalmic examination was performed before the procedure and at 1, 4, 10 days and each month. The primary efficacy was evaluated at 4 months from the HIFU treatment and in case of failure in target intraocular pressure (IOP) achievement we performed an additional treatment. A maximum of 3 procedures were performed.


The mean preoperative IOP was 33.8 mmHg ± 10,5. Four months after the first HIFU treatment 13 of the 24 treated eyes didn’t achieved the target IOP even a mean IOP reduction of 23% (postoperative IOP 26 mmHg ± 7.9). After the second HIFU procedures the mean IOP reduction was 25% (postoperative IOP 21.7 mmHg ± 7.7) and 40% from baseline. Five of 13 eyes needed a third treatment and 4 months after the mean IOP reduction was 25.6% (postoperative IOP 19.2 mmHg ± 5.5). From baseline total mean IOP reduction after the third HIFU was 41%.


No mayor complications occurred during any of the procedures, multiple HIFU treatments are safe and increase the overall efficacy.

Financial Disclosure:


Back to previous